Asia Spotlight: New Strategies Needed As China Shakes Up Drug Classes?
Executive Summary
In a fundamental shakeup of chemical drug classifications in China, foreign imported products are now in a class of their own while domestic drugs will be considered generics unless they are NCEs or have new formulations or indications. The changes are set to change the competitive landscape in profound ways, industry observers predict.
You may also be interested in...
Revised China Drug Regulation Sets Back IPR Protection – Experts
Long-awaited revised draft of China’s main drug registration regulation has legal experts wondering whether the China FDA is opening the flood gates to generic copies of new drugs due to a loosening of patent linkage provisions. Lack of provisions on review time limits and multiregional trials also disappoint some, although new OTC moves may be positive.
Revised China Drug Regulation Sets Back IPR Protection – Experts
Long-awaited revised draft of China’s main drug registration regulation has legal experts wondering whether the China FDA is opening the flood gates to generic copies of new drugs due to a loosening of patent linkage provisions. Lack of provisions on review time limits and multiregional trials also disappoint some, although new OTC moves may be positive.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.